Digital Therapeutics Sarcopenia Market Report 2025

The digital therapeutics sarcopenia market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to the increasing aging population, rising prevalence of age-related muscle loss, growing awareness of sarcopenia, expanding adoption of telehealth services, rising demand for home-based rehabilitation solutions, and supportive government initiatives promoting digital healthcare.

The digital therapeutics sarcopenia market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2029 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to the rising aging population, increasing focus on preventive muscle health, growing integration of AI in digital therapeutics, expanding reimbursement policies for digital therapeutics (DTx), development of personalized exercise programs, strengthening partnerships between technology firms and healthcare providers, and rising demand for remote rehabilitation solutions. Major trends during this period include advancements in AI-driven personalized exercise programs, integration with wearable health trackers, expansion of tele-rehabilitation platforms, adoption in elderly care, enhanced remote patient monitoring, and innovations in digital health solutions.

The rising prevalence of comorbidities is expected to drive the growth of the digital therapeutics sarcopenia market going forward. Comorbidities refer to the coexistence of two or more health conditions in a single individual. The increase in comorbidities is primarily driven by the aging population, as advancing age raises the risk of developing multiple chronic conditions due to declining physiological functions and prolonged exposure to health risks. Digital therapeutics for sarcopenia are effective in preventing comorbidities, particularly obesity, by encouraging regular physical activity and muscle strengthening, which improve metabolism and reduce fat accumulation. For example, in March 2024, the World Obesity Federation, a UK-based membership organization, reported that nearly 79% of adults affected by overweight and obesity are projected to reside in low- and middle-income nations by 2035, with the total number of adults with obesity expected to reach 1.53 billion. Therefore, the rising prevalence of comorbidities is supporting the growth of the digital therapeutics sarcopenia market.

Key companies in the digital therapeutics sarcopenia market are focusing on developing advanced solutions, such as drug discovery platforms, to create more targeted therapies, improve treatment efficacy, and accelerate personalized care for age-related muscle loss. A drug discovery platform enables faster and more efficient identification and development of new drugs using advanced tools and methods. For instance, in April 2025, ProFuse Technology, an Israel-based biotechnology company, introduced a drug discovery platform aimed at preventing muscle loss caused by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. By using lab-grown, highly mature muscle tissues that replicate natural muscle, the company can test and screen drug candidates more accurately and efficiently. This innovative platform reduces dependency on animal testing and lowers research costs. With rising demand for muscle-preserving therapies, ProFuse is expanding from cultivated meat into biopharma, offering a pioneering approach to tackle growing muscle health challenges.

In August 2023, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Versanis Bio for $1.9 billion. This acquisition expanded Lilly's portfolio to include Versanis’ main asset, bimagrumab, which is currently being evaluated in Phase 2b trials both alone and in combination with semaglutide for individuals with overweight or obesity. Versanis Bio, a US-based pharmaceutical company, specializes in developing therapies for sarcopenia, and this acquisition strengthens Eli Lilly’s presence in treatments targeting obesity and muscle loss.

Major players in the digital therapeutics sarcopenia market are Noom Inc., Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Virta Health Corp., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Propeller Health, Lark Technologies Inc., mySugr GmbH, SilverCloud Health Limited (a part of Amwell), Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, and Cometa Srl.

North America was the largest region in the digital therapeutics sarcopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digital therapeutics sarcopenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the digital therapeutics sarcopenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Digital therapeutics for sarcopenia refer to clinically validated, software-driven interventions designed to prevent, manage, or treat sarcopenia, a condition marked by progressive loss of muscle mass, strength, and functionality. These interventions utilize digital platforms to deliver personalized treatment strategies based on clinical evidence and behavioral science.

The primary products of digital therapeutics for sarcopenia include software, devices, and services. The software delivers tailored interventions such as exercise programs and nutrition plans via digital devices to help users manage muscle loss and support recovery. These solutions are distributed through online platforms, pharmacies, and other channels, with applications including muscle strengthening, physical activity monitoring, and nutrition management. End users include hospitals, clinics, homecare settings, rehabilitation centers, and others.

The digital therapeutics sarcopenia market research report is one of a series of new reports that provides digital therapeutics sarcopenia market statistics, including the digital therapeutics sarcopenia industry global market size, regional shares, competitors with the digital therapeutics sarcopenia market share, detailed digital therapeutics sarcopenia market segments, market trends, and opportunities, and any further data you may need to thrive in the digital therapeutics sarcopenia industry. This digital therapeutics sarcopenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The digital therapeutics sarcopenia market consists of revenues earned by entities by providing services such as software-driven therapeutic interventions, integration of predictive analytics, and delivery of rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics sarcopenia market also includes sales of wearable devices, biosensors, and virtual and augmented reality tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.